Cargando…

Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines

BACKGROUND: Integrase defective lentiviral vectors (IDLV) represent a promising delivery system for immunization purposes. Human dendritic cells (DC) are the main cell types mediating the immune response and are readily transduced by IDLV, allowing effective triggering of in vitro expansion of antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Negri, Donatella RM, Rossi, Alessandra, Blasi, Maria, Michelini, Zuleika, Leone, Pasqualina, Chiantore, Maria Vincenza, Baroncelli, Silvia, Perretta, Gemma, Cimarelli, Andrea, Klotman, Mary E, Cara, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468359/
https://www.ncbi.nlm.nih.gov/pubmed/22913641
http://dx.doi.org/10.1186/1742-4690-9-69
_version_ 1782245935137423360
author Negri, Donatella RM
Rossi, Alessandra
Blasi, Maria
Michelini, Zuleika
Leone, Pasqualina
Chiantore, Maria Vincenza
Baroncelli, Silvia
Perretta, Gemma
Cimarelli, Andrea
Klotman, Mary E
Cara, Andrea
author_facet Negri, Donatella RM
Rossi, Alessandra
Blasi, Maria
Michelini, Zuleika
Leone, Pasqualina
Chiantore, Maria Vincenza
Baroncelli, Silvia
Perretta, Gemma
Cimarelli, Andrea
Klotman, Mary E
Cara, Andrea
author_sort Negri, Donatella RM
collection PubMed
description BACKGROUND: Integrase defective lentiviral vectors (IDLV) represent a promising delivery system for immunization purposes. Human dendritic cells (DC) are the main cell types mediating the immune response and are readily transduced by IDLV, allowing effective triggering of in vitro expansion of antigen-specific primed CD8+ T cells. However, IDLV expression in transduced DC is at lower levels than those of the integrase (IN) competent counterpart, thus requiring further improvement of IDLV for future use in the clinic. RESULTS: In this paper we show that the addition of simian immunodeficiency (SIV)-Vpx protein in the vector preparation greatly improves transduction of human and simian DC, but not of murine DC, thus increasing the ability of transduced DC to act as functional antigen presenting cells, in the absence of integrated vector sequences. Importantly, the presence of SIV-Vpx allows for using lower dose of input IDLV during in vitro transduction, thus further improving the IDLV safety profile. CONCLUSIONS: These results have significant implications for the development of IDLV-based vaccines.
format Online
Article
Text
id pubmed-3468359
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34683592012-10-11 Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines Negri, Donatella RM Rossi, Alessandra Blasi, Maria Michelini, Zuleika Leone, Pasqualina Chiantore, Maria Vincenza Baroncelli, Silvia Perretta, Gemma Cimarelli, Andrea Klotman, Mary E Cara, Andrea Retrovirology Research BACKGROUND: Integrase defective lentiviral vectors (IDLV) represent a promising delivery system for immunization purposes. Human dendritic cells (DC) are the main cell types mediating the immune response and are readily transduced by IDLV, allowing effective triggering of in vitro expansion of antigen-specific primed CD8+ T cells. However, IDLV expression in transduced DC is at lower levels than those of the integrase (IN) competent counterpart, thus requiring further improvement of IDLV for future use in the clinic. RESULTS: In this paper we show that the addition of simian immunodeficiency (SIV)-Vpx protein in the vector preparation greatly improves transduction of human and simian DC, but not of murine DC, thus increasing the ability of transduced DC to act as functional antigen presenting cells, in the absence of integrated vector sequences. Importantly, the presence of SIV-Vpx allows for using lower dose of input IDLV during in vitro transduction, thus further improving the IDLV safety profile. CONCLUSIONS: These results have significant implications for the development of IDLV-based vaccines. BioMed Central 2012-08-22 /pmc/articles/PMC3468359/ /pubmed/22913641 http://dx.doi.org/10.1186/1742-4690-9-69 Text en Copyright ©2012 Negri et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Negri, Donatella RM
Rossi, Alessandra
Blasi, Maria
Michelini, Zuleika
Leone, Pasqualina
Chiantore, Maria Vincenza
Baroncelli, Silvia
Perretta, Gemma
Cimarelli, Andrea
Klotman, Mary E
Cara, Andrea
Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title_full Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title_fullStr Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title_full_unstemmed Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title_short Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
title_sort simian immunodeficiency virus-vpx for improving integrase defective lentiviral vector-based vaccines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468359/
https://www.ncbi.nlm.nih.gov/pubmed/22913641
http://dx.doi.org/10.1186/1742-4690-9-69
work_keys_str_mv AT negridonatellarm simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT rossialessandra simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT blasimaria simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT michelinizuleika simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT leonepasqualina simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT chiantoremariavincenza simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT baroncellisilvia simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT perrettagemma simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT cimarelliandrea simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT klotmanmarye simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines
AT caraandrea simianimmunodeficiencyvirusvpxforimprovingintegrasedefectivelentiviralvectorbasedvaccines